CLEVELAND, Oct. 21, 2020 /PRNewswire/ -- ViewRay, Inc.
(Nasdaq: VRAY) announced today that the company's MRIdian® Linac
MRI-guided radiation therapy system will be featured at the 2020
Annual Meeting of the American Society for Radiation Oncology
(ASTRO), being held virtually October 24 to
28, 2020. The meeting will feature presentations that
showcase the MRIdian system, including how clinicians use this
cutting-edge Stereotactic MRI-Guided Adaptive Radiation Therapy
(SMART) technology to tackle both tough-to-treat and ubiquitous
cancer, expand clinical experience with the device, and impact
patient outcomes.
At this year's virtual ASTRO meeting, nearly 40 scientific
session presentations/posters will highlight the important role of
MRIdian in cancer care, including data bolstering its clinical
value in the treatment of pancreas, prostate and tough-to-treat
tumors such as oligometastases and renal cancer. With the clarity
provided by MRIdian's real-time imaging and automatic beam gating,
physicians are equipped to account for anatomical changes and
motion caused by respiration or other bodily processes to
personalize treatment to the patient's unique needs.
- Acibadem Maslak Hospital will present its data on MRIdian
treatment for low- to intermedia-risk prostate cancer patients.
This study complements the Amsterdam University Medical Centers
studies on patients with intermediate- to high-risk prostate
cancer, where no fiducials were required and which resulted in
fewer grade 2 toxicities than published data*.
-
- Wednesday October 28,
2:00 PM – 3:00
PM ET
PV 07 - Poster Q&A - Session 7 4130
- Weill Cornell/NewYork-Presbyterian,
the Miami Cancer Institute (MCI), and the Moffitt Cancer Institute
are among the institutions presenting on their experiences using
SMART for pancreas cancer. Findings are expected to strengthen the
current body of literature, with SMART helping clinicians drive
positive patient outcomes and new insights on volumes and
survivability.
-
- Monday, October 26, 11:45 AM – 11:50 AM
ET
QP 12 - GI 02 - Hypofractionation in GI Cancers
Monday, October 26, 2:00 PM – 3:00 PM
ET
PV 04 - Poster Q&A - Session 4 3426, 3363, &
3325
- Amsterdam University Medical Centers and MCI will share data on
utilization of SMART for tough-to-treat tumors, including renal
cancer and abdominal oligomets, treated with radiation therapy and
immunotherapy.
-
- Monday, October 26, 2:00 PM – 3:00 PM
ET
PV 04 - Poster Q&A - Session 4 4407,
2405
As part of ASTRO's Innovation Hub, a dedicated space within the
virtual platform to highlight new technologies and innovations,
ViewRay will host two brief Innovation Hub presentations on
MRIdian's capabilities and a presentation on workflow and
efficiency by Justin Rineer, M.D.,
Radiation Oncologist at Orlando Health UF Health Cancer Center. The
company will also host an Industry Expert Theater presentation
featuring experts from the Dana -Farber/Brigham Women's Cancer Center discussing their
MRIdian clinical experience:
- Innovation in Action: What's next for MRIdian
Sunday, October 25, 12:00 –
12:15 pm ET
- Innovation in Action: Real-Time, On-Table Adaptive
Tuesday, October 27, 11:30 –
11:45 am ET
- Innovation in Action: MRIdian® Solutions for Streamlining
Workflow and Improving Efficiency
Monday, October 26, 10:30 –
11:30 am ET
- Industry Expert Theater: Maximizing Clinical Value of MRIdian,
featuring Dana -Farber/Brigham
Women's Cancer Center
Tuesday, October 27, 11:00 am – 12:00 pm
ET
To visit ViewRay's virtual booth and for a full schedule of the
MRIdian-focused presentations at ASTRO 2020 please visit
https://viewray.com/events-webinars. ViewRay's booth will feature
information including:
- Experience MRIdian: Treat and Prove what Others Can't
(Demo and more)
- The Patient Experience: Latest Videos
- Innovation Value: See What's New with Technology and
Treatment
- Clinical Value: See the Results
- MRIdian in Action: Learn More About our Customer
Experience
- The Economic Value of MRIdian: The Financial Benefits of
Introducing a New Service Line
Additionally, ViewRay will host a physician-led webinar for
investors and analysts on Tuesday, October
27, 2020 at 11:00 am ET.
Registration is required to attend and will close an hour prior to
the start. Please register at
https://www.bigmarker.com/viewray/Physician-led-Webinar-for-Investors-and-Analysts-at-2020-ASTRO-Annual-Meeting?utm_bmcr_source=Press.
Currently 40 MRIdian systems are installed at hospitals around
the world, where they are used to treat a wide variety of solid
tumors and are the focus of numerous ongoing research efforts.
MRIdian has been the subject of hundreds of peer-reviewed
publications, scientific meeting abstracts and presentations. More
than 10,000 patients have been treated with MRIdian. For a list of
treatment centers, please visit:
https://viewray.com/find-mridian-mri-guided-radiation-therapy/
* Dearnaley D, Syndikus I, Mossop H, et al. Conventional
versus hypofractionated high-dose intensity modulated radiotherapy
for prostate cancer: 5-year outcomes of the randomised,
non-inferiority, phase 3 CHHiP trial. Lancet Oncol. 2016
Aug;17(8):1047-10.
About ViewRay
ViewRay, Inc. (Nasdaq: VRAY), designs,
manufactures and markets the MRIdian radiation therapy system.
MRIdian is built upon a proprietary high-definition MR imaging
system designed from the ground up to address the unique challenges
and clinical workflow for advanced radiation oncology. Unlike MR
systems used in diagnostic radiology, MRIdian's high-definition MR
was purpose built to address specific challenges, including beam
distortion, skin toxicity, and other concerns that potentially may
arise when high magnetic fields interact with radiation beams.
ViewRay and MRIdian are registered trademarks of ViewRay, Inc.
Forward-Looking Statements
This press release contains
forward-looking statements within the meaning of Section 27A of the
Private Securities Litigation Reform Act. Statements in this press
release that are not purely historical are forward-looking
statements. Such forward-looking statements include, among other
things, the rate of new orders, upgrades, and installations,
ViewRay's anticipated future operating and financial performance,
and ViewRay's conference calls to discuss its quarterly results.
Actual results could differ from those projected in any
forward-looking statements due to numerous factors. Such factors
include, among others, the ability to commercialize MRIdian Linac
System, demand for ViewRay's products, the ability to convert
backlog into revenue, the timing of delivery of ViewRay's products,
the timing, length, and severity of the recent COVID-19
(coronavirus) pandemic, including its impacts across our businesses
on demand, operations and our global supply chains, the results and
other uncertainties associated with clinical trials, the ability to
raise the additional funding needed to continue to pursue ViewRay's
business and product development plans, the inherent uncertainties
associated with developing new products or technologies,
competition in the industry in which ViewRay operates, and overall
market conditions. For a further description of the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to ViewRay's business in general, see ViewRay's current
and future reports filed with the Securities and Exchange
Commission, including its Annual Report on Form 10-K for the fiscal
year ended December 31, 2019 and its
Quarterly Reports on Form 10-Q, as updated periodically with the
company's other filings with the SEC. These forward-looking
statements are made as of the date of this press release, and
ViewRay assumes no obligation to update the forward-looking
statements, or to update the reasons why actual results could
differ from those projected in the forward-looking statements,
except as required by law.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/astro-2020-to-feature-latest-mridian-clinical-experience-highlighting-outcomes-in-tough-to-treat-cancer-301156595.html
SOURCE ViewRay, Inc.